



# CLINICAL TRIALS

## Treatment & Research In Psychedelics (TRIP) PACIFIC NEUROSCIENCE INSTITUTE®

Treatment & Research In Psychedelics<sup>SM</sup> (TRIP<sup>SM</sup>) at Pacific Neuroscience Institute® conducts state-of-the art clinical trials of psychedelic therapies including investigator-initiated and industry-sponsored trials.

### SET & SETTING

- » TRIP has 2 psychedelic dosing “trip” rooms equipped with a couch and comfortable chairs, audio-video sound system, blood pressure/heart rate/pulse oximetry monitor, and décor designed to create a calm, supportive, and safe environment for psychedelic sessions.
- » Group counseling/meditation room.
- » Secure medication storage room including 1,200 pound safe equipped with alarm for schedule I controlled substance storage, a separate safe for schedule III-V substances, a locking refrigerator, and alarm system with 24/7 monitoring of camera and motion detectors.
- » Current DEA Schedule I researcher registration active.
- » Medical exam room with exam table, sink, ophthalmoscope/otoscope.
- » Emergency resuscitation equipment including AED, oxygen, suction.
- » Research staff work room.
- » High speed internet on the secure Providence Health network with multiple workstations for data collection and EPIC EHR use.
- » On-site phlebotomy, lab testing, and diagnostic studies (EKG).
- » Emergency medical services (fire and police) and Saint John’s Health Center Emergency Department one-block from the clinic.
- » We conduct ketamine-assisted psychotherapy and clinical trials.

### GUIDES

- » The clinic is staffed by two physicians (internal medicine/addiction medicine and psychiatry), three lead therapist/psychedelic facilitators, multiple affiliated clinician psychedelic co-facilitators, medical assistants, front office staff, research coordinators and research assistants.
- » Five lead physician/therapist/facilitators have completed the year-long psychedelic therapy certificate program at California Institute of Integral Studies and have hands-on experience treating patients in psychedelic clinical trials.
- » The staff and resources needed to support the required regulatory monitoring (IRB, FDA, DEA, RAP-C, quality assurance) are available within the Pacific Brain Health Center.

TRIP DIRECTOR: Keith Heinzerling, MD  
TRIP FOUNDER: Daniel F. Kelly, MD



# ABOUT US

## Treatment & Research In Psychedelics (TRIP) PACIFIC NEUROSCIENCE INSTITUTE®

Ranked among the top neurology and neurosurgery programs, Pacific Neuroscience Institute is a local and global destination providing compassionate care for complex diseases across the neurosciences.

**CLINICAL TRIALS to date:** Major Depression, Alcohol Use Disorder, Generalized Anxiety Disorder

**MEDICINES used to date:** Psilocybin, LSD, ketamine

**CLINICAL TRIAL PATIENTS:**

- » Track record as high enrolling site for psychedelic trials
- » Part of large Providence health network for efficient study recruitment

**PUBLICATIONS:** Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology *Neurosurgery Dec 2022*

Nature-themed Video Intervention May Improve Cardiovascular Safety of Psilocybin-assisted Therapy For Alcohol Use Disorder  
*In review at Frontiers of Psychiatry 2023*

**About the TRIP Program:** The TRIP Program was formed in June 2019 within the Pacific Brain Health Center with a mission dedicated to the development of psychedelic-assisted therapies and the scientific exploration of how altered states of consciousness can be harnessed to change behavior and improve brain health and quality of life.

Over the last 4 years, under the leadership of Dr. Keith Heinzerling (Program Director) and Dr. Daniel Kelly (PNI Director and Founder), the TRIP Program has expanded in terms of team members, clinical productivity, clinical trials, and notoriety. With the combined resources of the PNI Foundation and Providence Saint John's Health Center, we are equipped to carry out state-of-the-art clinical trials of psychedelic-assisted therapies including investigator-initiated and industry sponsored trials.

**About PNI:** Pacific Neuroscience Institute® (PNI®) was founded in 2015 by Daniel F. Kelly, MD, Chester F. Griffiths, MD, Howard R. Krauss, MD, and Santosh Kesari, MD, PhD. The founders' vision was to create a unique institute in which subspecialists across multiple disciplines work collaboratively under one roof to promote brain health. The PNI Medical Group faculty provide multidisciplinary care across 12 specialties and 10 Centers of Excellence, advance novel care paradigms through clinical trials and refinement of minimally invasive and non-invasive treatments, and conduct neuroscience training, and community outreach.

In 2022, PNI faculty had over 65,000 patient clinic visits and performed over 3,000 surgical or neuro-interventional radiology procedures. PNI has

participated in over 30 recently completed or active clinical trials spanning addiction, anxiety, depression, dementia, Parkinson's disease, benign and malignant brain tumors, stroke and hydrocephalus. Since 2015, our PNI faculty have authored over 200 academic peer-reviewed publications (including 46 in 2022) detailing the outcomes of our innovative approaches and clinical trials. Many of our more than 40 PNI faculty are engaged in fellowship training, graduate, nursing and medical assistant education, and teach or lecture at national and international meetings. Through our PNI website [pacificneuro.org](http://pacificneuro.org), with over a million visits annually, PNI provides ongoing neuroscience education to the community at large through our content, blogs, podcasts, videos, newsletters, and social media channels.

**FOR MORE INFORMATION:**  
310-582-7611 | [PacificNeuro.org](http://PacificNeuro.org)



TRIP<sup>SM</sup>

Treatment & Research In Psychedelics

**PACIFIC  
NEUROSCIENCE  
INSTITUTE®**